Business Context and Reporting Period
Organogenesis Holdings Inc. filed this Form 8-K on May 10, 2023, to announce its financial results for the fiscal first quarter ended March 31, 2023. The company is incorporated in Delaware and trades on the Nasdaq Capital Market under the symbol ORGO.
Key Financial Metrics
The filing text does not provide specific numerical values for revenue, profit, cash flow, margins, debt, or liquidity. These details are contained within the press release attached as Exhibit 99.1, which is incorporated by reference but not reproduced in the body of this 8-K.
Material Changes
The filing does not disclose specific material changes versus the prior comparable period. It serves solely as a notification that the Q1 2023 results have been announced via a separate press release.
Guidance, Outlook, and Risks
The filing does not contain management commentary, guidance, outlook, or specific risk factors. It explicitly states that the information in the attached press release is furnished and not deemed "filed" for purposes of Section 18 of the Exchange Act, nor is it incorporated by reference in other filings except as expressly set forth.
Investor Verification Checklist
- Review the full text of the press release (Exhibit 99.1) for specific Q1 2023 financial figures.
- Verify the company's liquidity position and debt obligations in the detailed financial statements referenced in the press release.
- Check for any forward-looking statements or guidance updates included in the separate press release.
- Confirm the status of the company's emerging growth company election, which is not checked in this filing.